Cargando…

TERT Mutation Is Accompanied by Neutrophil Infiltration and Contributes to Poor Survival in Isocitrate Dehydrogenase Wild-Type Glioma

Mutation of the telomerase reverse transcriptase (TERT) promoter has been demonstrated as an unfavorable prognostic marker in patients with isocitrate dehydrogenase wild-type (IDHwt) glioma. This study aimed to investigate the immune role of TERT promoter mutation status which could improve prognost...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gao, Mengqi, Lin, Yi, Liu, Xing, Zhao, Zheng, Zhu, Zhiyuan, Zhang, Hongbo, Ban, Yunchao, Bie, Yanan, He, Xiaozheng, Sun, Xiang, Zhang, Shizhong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Cell and Developmental Biology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8119999/ https://www.ncbi.nlm.nih.gov/pubmed/33996815 http://dx.doi.org/10.3389/fcell.2021.654407

Ejemplares similares

Wild-type isocitrate dehydrogenase under the spotlight in glioblastoma
por: Alzial, Gabriel, et al.
Publicado: (2021)

Outcomes of Isocitrate Dehydrogenase Wild Type Glioblastoma after Re-irradiation
por: Ehret, Felix, et al.
Publicado: (2023)

Oncogenic transgelin-2 is differentially regulated in isocitrate dehydrogenase wild-type vs. mutant gliomas
por: Beyer, Sasha J., et al.
Publicado: (2018)

An independently validated nomogram for isocitrate dehydrogenase-wild-type glioblastoma patient survival
por: Gittleman, Haley, et al.
Publicado: (2019)

Ivosidenib in Isocitrate Dehydrogenase 1–Mutated Advanced Glioma
por: Mellinghoff, Ingo K., et al.
Publicado: (2020)

Mutation of Isocitrate Dehydrogenase 1 in Cholangiocarcinoma Impairs Tumor Progression by Inhibiting Isocitrate Metabolism
por: Su, Li, et al.
Publicado: (2020)

Isocitrate dehydrogenase mutations in myeloid malignancies
por: Medeiros, B C, et al.
Publicado: (2017)

The prognostic significance of wild-type isocitrate dehydrogenase 2 (IDH2) in breast cancer
por: Aljohani, Abrar I., et al.
Publicado: (2019)

A Case of Glioblastoma, Isocitrate Dehydrogenase Wild Type, With Widely Disseminated Osseous Metastasis
por: Conte, Brianna, et al.
Publicado: (2022)

Pre-operative Neurocognitive Function Was More Susceptible to Decline in Isocitrate Dehydrogenase Wild-Type Subgroups of Lower-Grade Glioma Patients
por: Zhang, Zhe, et al.
Publicado: (2020)

Isocitrate Dehydrogenase Mutations in Glioma: Genetics, Biochemistry, and Clinical Indications
por: Liu, Yang, et al.
Publicado: (2020)

EGFRvIII expression and isocitrate dehydrogenase mutations in patients with glioma
por: Taher, Mohiuddin M., et al.
Publicado: (2020)

Advances in Immune Microenvironment and Immunotherapy of Isocitrate Dehydrogenase Mutated Glioma
por: Yan, Dongming, et al.
Publicado: (2022)

Adult isocitrate dehydrogenase–mutant brainstem glioma: illustrative case
por: Ye, Vincent C., et al.
Publicado: (2021)

Immunotherapy Approaches in Isocitrate-Dehydrogenase-Mutant Low-Grade Glioma
por: Gallus, Marco, et al.
Publicado: (2023)

Isocitrate dehydrogenase mutations in gliomas: A review of current understanding and trials
por: Sharma, Nikhil, et al.
Publicado: (2023)

Effect of Levetiracetam Use Duration on Overall Survival of Isocitrate Dehydrogenase Wild-Type Glioblastoma in Adults
por: King-Stephens, David
Publicado: (2022)

Wild-Type Isocitrate Dehydrogenase-Dependent Oxidative Decarboxylation and Reductive Carboxylation in Cancer and Their Clinical Significance
por: He, Qiwei, et al.
Publicado: (2022)

The T2-FLAIR mismatch sign in glioblastoma, isocitrate dehydrogenase wild-type A case report
por: Nishimura, Shunsuke, et al.
Publicado: (2023)

Isocitrate dehydrogenase inhibitors in acute myeloid leukemia
por: Liu, Xiaoyan, et al.
Publicado: (2019)

The Role of Isocitrate Dehydrogenases in Direct Reprogramming to Cardiomyocytes
por: Ishida, Tomoaki, et al.
Publicado: (2021)

Isocitrate Dehydrogenase Mutations in Glioma: From Basic Discovery to Therapeutics Development
por: Huang, Juan, et al.
Publicado: (2019)

Mutated Isocitrate Dehydrogenase (mIDH) as Target for PET Imaging in Gliomas
por: Neumaier, Felix, et al.
Publicado: (2023)

Association of Isocitrate Dehydrogenase (IDH) Status With Edema to Tumor Ratio and Its Correlation With Immune Infiltration in Glioblastoma
por: Dubinski, Daniel, et al.
Publicado: (2021)

Using radiomics based on multicenter magnetic resonance images to predict isocitrate dehydrogenase mutation status of gliomas
por: Liu, Yan, et al.
Publicado: (2023)

Profiling the Effect of Targeting Wild Isocitrate Dehydrogenase 1 (IDH1) on the Cellular Metabolome of Leukemic Cells
por: Shait Mohammed, Mohammed Razeeth, et al.
Publicado: (2022)

Mismatch repair protein mutations in isocitrate dehydrogenase (IDH)-mutant astrocytoma and IDH-wild-type glioblastoma
por: Richardson, Timothy E, et al.
Publicado: (2023)

PD-L1-Mediated Immunosuppression in Glioblastoma Is Associated With the Infiltration and M2-Polarization of Tumor-Associated Macrophages
por: Zhu, Zhiyuan, et al.
Publicado: (2020)

Isocitrate dehydrogenase 1 Gene Mutation Is Associated with Prognosis in Clinical Low-Grade Gliomas
por: Li, Ming-Yang, et al.
Publicado: (2015)

Isocitrate dehydrogenase mutations: new opportunities for translational research
por: Keum, Young-Sam, et al.
Publicado: (2015)

Isocitrate dehydrogenases in physiology and cancer: biochemical and molecular insight
por: Al-Khallaf, Hamoud
Publicado: (2017)

Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics
por: Golub, Danielle, et al.
Publicado: (2019)

Isocitrate dehydrogenase gene variants in cancer and their clinical significance
por: Cadoux-Hudson, Thomas, et al.
Publicado: (2021)

Metabolic adaptations in cancers expressing isocitrate dehydrogenase mutations
por: Hvinden, Ingvild Comfort, et al.
Publicado: (2021)

The regulatory mechanisms and inhibitors of isocitrate dehydrogenase 1 in cancer
por: Liu, Yang, et al.
Publicado: (2023)

Screening of Methylation Signature and Gene Functions Associated With the Subtypes of Isocitrate Dehydrogenase-Mutation Gliomas
por: Pan, XiaoYong, et al.
Publicado: (2019)

Clinico-neuropathological features of isocitrate dehydrogenase 2 gene mutations in lower-grade gliomas
por: Wang, Lei-Ming, et al.
Publicado: (2019)

Isocitrate dehydrogenase 1 mutation subtypes at site 132 and their translational potential in glioma
por: Lu, Victor M, et al.
Publicado: (2018)

Isocitrate dehydrogenase 1 mutation is associated with reduced levels of inflammation in glioma patients
por: Auezova, Raushan, et al.
Publicado: (2019)

Hub gene identification and prognostic model construction for isocitrate dehydrogenase mutation in glioma
por: Jia, Yanfei, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_aj8ksa71ihj3i8b8hbtq8ndsfm